Sort   by:  
 Page size 
UnknownSLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Not available
S-EPMC3138634 | biostudies-literature
TranscriptomicsProstate Cancer Gene Expression Changes after Treatment with Neoadjuvant Dutasteride
To identify molecular changes underlying the chemopreventive or tumor promoting effects of SRD5A inhibition, we profiled gene expression changes in benign prostate epithelium from patients with PCa treated with dutasteride, a dual SRD5A inhibitor. Subjects were aged 45-80 years with clinically local...
ORGANISM(S): Homo sapiens 
2008-12-01 | E-GEOD-9972 | biostudies-arrayexpress
TranscriptomicsProstate Cancer Gene Expression Changes with Neoadjuvant Hormone Therapy
Men with clinically localized prostate cancer were treated with 0 to 9 months of neoadjuvant hormone suppression prior to prostatectomy. Keywords: microarray, hormone, 9 men with prostate cancer were assigned to neoadjuvant hormone suppression therapy for 3-6, 6, or 0 months.
ORGANISM(S): Homo sapiens 
2008-12-01 | E-GEOD-9983 | biostudies-arrayexpress
TranscriptomicsTMPRSS2 Influences Prostate Cancer Metastasis
TMPRSS2 is an androgen-regulated cell surface serine protease expressed predominantly in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate cancers and in the majority of human prostate cancer metastasis. Through the generation of mouse models with a targeted deletion ...
ORGANISM(S): Mus musculus 
2014-09-09 | E-GEOD-58822 | biostudies-arrayexpress
Sort   by:  
 Page size